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ABSTRACT
The immunoglobulin heavy-chain variable region (IGHV) mutational status is 
a strong determinant of remission duration in chronic lymphocytic leukemia (CLL). 
The aim of this work was to compare the multidrug resistance (MDR) signature of 
IGHV mutated and unmutated CLL cells, identifying biochemical and molecular targets 
potentially amenable to therapeutic intervention.
We found that the mevalonate pathway-dependent Ras/ERK1–2 and RhoA/
RhoA kinase signaling cascades, and the downstream HIF-1α/P-glycoprotein axis 
were more active in IGHV unmutated than in mutated cells, leading to a constitutive 
protection from doxorubicin-induced cytotoxicity. The constitutive MDR phenotype 
of IGHV unmutated cells was partially dependent on B cell receptor signaling, as 
shown by the inhibitory effect exerted by ibrutinib. Stromal cells further protected 
IGHV unmutated cells from doxorubicin by upregulating Ras/ERK1–2, RhoA/RhoA 
kinase, Akt, HIF-1α and P-glycoprotein activities. Mevalonate pathway inhibition 
with simvastatin abrogated these signaling pathways and reversed the resistance of 
IGHV unmutated cells to doxorubicin, also counteracting the protective effect exerted 
by stromal cells. Similar results were obtained via the targeted inhibition of the 
downstream molecules ERK1–2, RhoA kinase and HIF-1α.
Therefore, targeting the mevalonate pathway and its downstream signaling cascades 
is a promising strategy to circumvent the MDR signature of IGHV unmutated CLL cells.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is chara­
cterized by a highly heterogeneous clinical course and a 
poor curability with conventional chemotherapy treatment 
approaches. The immunoglobulin heavy­chain variable 
region (IGHV) mutational status has emerged as a powerful 
prognosticator: patients with IGHV unmutated (UM) CLL 
cells display inferior survival rates [1, 2] and shorter complete 
remission duration than IGHV mutated (M) patients [3].
Stromal cells (SCs) are known to protect CLL cells 
from spontaneous apoptosis and drug­induced cytotoxicity. 
We previously reported that IGHV UM cells are more 
dependent than M cells on microenvironment­mediated 
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signals for their survival [4]. However, whether IGHV M 
and UM CLL cells differ for their ex vivo susceptibility to 
chemotherapy is controversial [5, 6].
Results from clinical trials have shown that 
fludarabine, even when used as a single agent, induced 
higher remission rates than other chemotherapies, such 
as CAP (cyclophosphamide, doxorubicin, prednisone) 
or CHOP (cyclophosphamide, doxorubicin, vincristine, 
prednisone), in previously untreated CLL patients [7, 
8]. However, the reasons accounting for the lower 
effectiveness of anthracycline­containing regimens in CLL 
remain largely unexplored.
One of the main mechanisms of chemoresistance 
is the overexpression of membrane transporters which 
actively extrude chemotherapy drugs, a process called 
multidrug resistance (MDR). Anthracyclines, such as 
doxorubicin (Doxo), are substrates of one of the best 
characterized drug efflux pump, the P-glycoprotein (Pgp/
ABCB1), which is encoded by the MDR1 gene [9].
Pgp activity is directly related to the amount of 
cell cholesterol in the plasma membrane [10], and its 
expression is regulated by the transcription factor hypoxia­
inducible factor-1 alpha (HIF-1α), whose activation 
is dependent on Ras/ERK1–2 and RhoA/RhoA kinase 
signaling pathways [11].
All these pathways are under the control of the 
mevalonate (Mev) pathway, a highly conserved metabolic 
cascade which produces sterols, such as cholesterol, 
and isoprenoids, such as farnesyl pyrophosphate (FPP) 
and geranylgeranyl pyrophosphate (GGPP). The latter 
are necessary for the isoprenylation of Ras and RhoA 
GTPases, and for the activation of their downstream 
signaling pathways [12].
The Mev pathway can be pharmacologically 
inhibited using statins (e.g. simvastatin, SIM) or amino­
bisphosphonates (e.g. zoledronic acid, ZA) [13], and we 
have already shown that ZA can restore the sensitivity of 
MDR positive (MDR+) solid tumor cell lines to Doxo [14].
CLL cells carrying IGHV UM genes have 
significantly higher levels of Mev pathway activity, which 
are thought amenable to pharmacological manipulation 
by SIM and ZA [15]. It is currently unknown whether 
the higher activity of the Mev pathway in IGHV UM 
cells translates into a MDR+ phenotype, and whether the 
targeted inhibition of the Mev pathway or downstream 
signaling can eventually counteract the MDR+ signature 
of CLL cells.
The aim of this study was twofold: 1) to 
characterize the MDR status of IGHV M and UM 
cells, by evaluating the activity of Ras/ERK1–2, 
RhoA/RhoA kinases, and HIF-1α/Pgp axis under basal 
conditions and after exposure to SCs; 2) to determine 
whether targeting the Mev pathway and its downstream 
signaling eventually restores the sensitivity of MDR+ 
CLL cells to Doxo.
RESULTS 
The Ras/ERK1–2 and RhoA/RhoA kinase 
signaling pathways and the HIF-1α/Pgp axis are 
more active in IGHV UM than M CLL cells
The activity of Ras­ and RhoA­dependent 
signaling pathways was analyzed in IGHV M and UM 
CLL cells (>90% pure as described below) after ex 
vivo culture for 24 hours. Both type of cells exhibited 
detectable amounts of non­isoprenylated cytosolic Ras 
and unphosphorylated ERK1–2, but only IGHV UM cells 
showed high intracellular levels of the Ras GTP­bound 
active form and the Ras­downstream effector kinase 
phospho-ERK1–2 (Figure 1A, left), in keeping with their 
accelerated Mev pathway activity [15]. Similarly, the 
amount of active GTP­bound RhoA and the activity of 
the downstream RhoA kinase were significantly higher in 
IGHV UM than M cells (p always = 0.001) (Figure 1A, 
right).
Both ERK1–2 and RhoA kinase phosphorylate 
and activate the transcription factor HIF-1α [16, 17]. 
Accordingly, the activation of Ras/ERK1–2 and RhoA/
RhoA kinase signalling pathways in IGHV UM cells led 
to the phosphorylation of HIF-1α (Supplementary Figure 
S1) and to the increase of its transcriptional activity, as 
shown by the significantly higher amounts of nuclear 
HIF-1α bound to its specific DNA target sequence (p = 
0.002) (Figure 1B, left). As a consequence, IGHV UM 
cells showed higher MDR1 mRNA expression (Figure 1B, 
right) and lower Doxo accumulation than IGHV M cells (p 
always = 0.001) (Figure 1C).
In agreement with our previous data [4], both 
untreated IGHV M and UM cells showed high levels of 
viability after ex vivo culture for 48 hours, whereas Doxo 
treatment induced a significant decrease of viability in 
IGHV M compared to UM CLL cells (p = 0.001) (Figure 
1D and Supplementary Figure S2).
The constitutive MDR phenotype of IGHV UM 
cells depends on BCR signaling and is further 
upregulated by SC-mediated extrinsic signals
IGHV UM cells display an increased signaling 
through the B cell receptor (BCR) compared to IGHV M 
cells [18]. To study the effect of BCR signaling on Mev­
regulated pathways and MDR phenotype we incubated 
IGHV M and UM cells with anti­IgM antibody, in the 
presence or absence of the Bruton tyrosine kinase (BTK) 
inhibitor ibrutinib. Anti­IgM­mediated BCR stimulation 
did not increase the baseline production of cholesterol 
and FPP (Figure 2A), the amount of GTP­bound 
RhoA and the activity of RhoA kinase (Figure 2B), the 
transcriptional activity of HIF-1α and the expression of 
its target gene MDR1 (Figure 2C) in both IGHV M and 
UM cells. Of note, ibrutinib­mediated BCR inhibition 
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significantly decreased the constitutively higher levels of 
cholesterol and FPP production, RhoA and RhoA kinase 
activity, HIF-1α transcriptional activity and MDR1 
expression in IGHV UM cells (p always ≤ 0.05), whereas 
it did not affect the Mev pathway and Mev­regulated 
signaling in IGHV M cells.
SCs are known to confer a chemoresistant phenotype 
to CLL cells [19–21]. Therefore, we also sought whether 
IGHV M and UM cells co­cultured with the murine 
stromal cell line M2–10B4 upregulated the Mev pathway 
and the RhoA/RhoA kinase signaling pathways. IGHV M 
and UM cells showed high and comparable levels of cell 
viability after 24­hour ex vivo culture, both in the presence 
and in the absence of SCs (data not shown). After exposure 
to M2–10B4 SCs, the production of cholesterol and FPP 
(Figure 3A), the amount of GTP­bound RhoA and the 
activity of RhoA kinase (Figure 3B), the transcriptional 
activity of HIF-1α, and the expression of its target gene 
MDR1 (Figure 3C) were significantly increased in IGHV 
UM but not in M CLL cells (p always ≤ 0.03).
SIM effectively reverses the MDR phenotype 
of IGHV UM cells and restores Doxo-induced 
cytotoxicity
We next examined whether SIM, which switches off 
the Mev pathway downstream to the rate­controlling enzyme 
3­hydroxy­3­methyl­glutaryl­CoA reductase, was effective in 
reversing the MDR phenotype of IGHV UM cells.
In IGHV UM cells, SIM significantly reduced 
cholesterol and FPP production (p always ≤ 0.05) (Figure 4A), 
the amounts of GTP-bound Ras and phospho-ERK1–2 kinases 
(Figure 4B), the amounts of GTP­bound RhoA and the activity 
of RhoA kinase (Figure 4C), also abrogating the upregulating 
effect exerted by M2–10B4 SCs (p always ≤ 0.0005).
This SIM­mediated inhibition of the Mev pathway 
and downstream signaling pathways was paralleled by a 
lower HIF-1α phosphorylation (Supplementary Figure S3) 
and a statistically significant decrease in HIF-1α activity and 
MDR1 expression in IGHV UM cells, both in the presence 
or absence of SCs (p always < 0.003) (Figure 5A, 5B). Thus, 
Figure 1: The Ras/ERK1–2 and RhoA/RhoA kinase signaling pathways and the HIF-1α/Pgp axis are more active in 
IGHV UM than M CLL cells. The activity of the Ras/ERK1–2 and RhoA/RhoA kinase signaling cascades and the HIF-1α/Pgp axis 
were measured in CLL cells isolated from the peripheral blood of IGHV M and UM patients after 24­hour ex vivo culture. A. Ras and 
ERK1–2 kinase activities were measured by Western Blot (WB) (left side). IGHV UM cells have a higher expression of the active forms of 
Ras (Ras GTP) and ERK1–2 (pERK1–2), than IGHV M cells. Results are from 3 representative experiments for both M and UM patients 
(UPN, unique patient number). RhoA GTP and RhoA Kinase activities were measured by ELISA assays (right side). IGHV UM cells have 
higher activities of RhoA GTP and RhoA Kinase compared to M cells (*p = 0.001). B. HIF-1α activity and MDR1 mRNA expression. IGHV 
UM cells have higher HIF-1α activity compared to M cells (*p = 0.002) after 24 hours of culture. At the same time-point, significantly 
higher MDR1 levels were observed in IGHV UM cells than in M cells (*p = 0.001). C. Intracellular Doxo accumulation. Significantly lower 
concentrations of Doxo were detected after 48­hour ex vivo exposure in IGHV UM than in M cells (*p = 0.001). D. Viability of CD19+/
CD5+ cells was determined by Annexin-V (Ann-V) staining and cytofluorimetric analysis after 48-hour Doxo exposure. IGHV UM cells 
showed higher levels of viability than M cells (*p = 0.001). Results are from 7 experiments for both M and UM patients. In all panels, bars 
represent mean values ± SEM.
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SIM significantly increased the accumulation of intracellular 
Doxo, even in the presence of SCs (p always ≤ 0.002) (Figure 
5C). The SIM­induced increase in Doxo accumulation 
determined an enhanced cytotoxic death of IGHV UM cells 
after exposure to the combination SIM+Doxo for 48 hours (p 
≤ 0.0001). Interestingly, SIM was also effective in reversing 
the protective effect exerted by M2–10B4 SCs (p ≤ 0.0001) 
(Figure 5D and Supplementary Figure S4).
SIM effectively abrogates SC-induced Akt 
upregulation in IGHV UM cells
We next examined the effect of another Mev pathway 
inhibitor, ZA, which switches off the pathway downstream 
to FPP-synthase. ZA significantly abrogated cholesterol and 
FPP synthesis in IGHV UM cells cultured alone (p ≤ 0.05), 
and also in IGHV UM cells cultured with M2–10B4 SCs (p 
≤ 0.03) (Supplementary Figure S5A, S5B). Moreover, ZA 
was effective in reducing the amount of the active GTP­
bound form of Ras and phospho-ERK1–2, even in the 
presence of the M2–10B4 SCs (Supplementary Figure S5C, 
S5D). Similarly, the exposure of IGHV UM cells to ZA 
significantly reduced the amount of the active GTP-bound 
form of RhoA and the activity of the downstream RhoA 
kinase, irrespective of the presence or absence of SCs (p 
always ≤ 0.01) (Supplementary Figure S5E, S5F).
The inhibition of Ras/ERK1–2 and RhoA/RhoA 
kinase signaling was paralleled by a reduction of HIF­
1α phosphorylation (Supplementary Figure S6), and 
a significant decrease in HIF-1α activity and MDR1 
expression in the presence or absence of SCs (p always ≤ 
0.05) (Supplementary Figure S7A, S7B).
Figure 2: Ibrutinib inhibits the Mev pathway activity, the RhoA/RhoA kinase cascade and the HIF-1α/Pgp axis in 
IGHV UM but not in IGHV M cells. IGHV M and UM cells were stimulated for 24 hours with anti-IgM (10 μg/well) in the absence 
or presence of 30-minute pre-incubation with ibrutinib (1 μM). A. Cholesterol and FPP production. Anti­IgM stimulation did not increase 
cholesterol and FPP production in IGHV M and UM cells. IgM+ibrutinib significantly reduced the levels of cholesterol and FPP in IGHV 
UM cells (*p = 0.04 and *p = 0.05, respectively). B. RhoA and RhoA kinase activity. Anti­IgM stimulation had no effect on RhoA­GTP 
expression and RhoA kinase activity in IGHV M and UM cells. The amount of GTP­bound RhoA and the activity of the RhoA kinase were 
significantly reduced by IgM+ibrutinib in IGHV UM cells (*p = 0.0015 and *p = 0.0021, respectively), but not in IGHV M cells. C. HIF-1α 
activity and MDR1 expression. Anti-IgM stimulation did not increase HIF-1α activity and MDR1 expression in IGHV M and UM cells. 
The activity of HIF-1α and MDR1 expression were significantly reduced by IgM+ibrutinib in IGHV UM cells (*p = 0.01 and *p = 0.0012, 
respectively), but not in IGHV M cells. In all panels, bars represent mean values ± SEM of side-by-side experiments performed in replicates.
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Unlike SIM, ZA was unable to increase Doxo 
accumulation and Doxo­induced cytotoxicity in IGHV 
UM cells cultured in the presence or in the absence of 
M2–10B4 SCs (Supplementary Figure S7C, S7D).
To further elucidate the difference between ZA 
and SIM, we also evaluated the effects on Akt and NF-
kB, which are well­known pro­survival factors for CLL 
cells [22]. The baseline activity of Akt, but not that of NF-
kB, was significantly higher in IGHV UM than M cells 
(p ≤0.001) (Figure 6A, 6B). The same results were 
confirmed by evaluating the expression of the active 
phosphorylated form of Akt and the nuclear translocation 
of the NF-kB components p50 and p65 by western blot 
analyses (Supplementary Figure S8A, S8B).
Akt activity was further upregulated by the presence 
of M2–10B4 SCs (Figure 5C and Supplementary Figure 
S9A), whereas NF-kB activity was not, as previously 
reported [4]. ZA significantly increased Akt activity in 
IGHV UM cells (p ≤ 0.009), and this effect was particularly 
evident when ZA and SCs were used in combination (p 
≤ 0.03) (Supplementary Figure S9A). Of note, ZA also 
increased NF-kB activity in IGHV UM cells, both in the 
absence and in the presence of SCs (p ≤ 0.05 and p ≤ 0.04, 
respectively) (Supplementary Figure S9B). Unlike ZA, SIM 
reduced the baseline Akt and NF-kB activities (p ≤ 0.02), 
and significantly abrogated the SC-induced up-regulation 
of Akt and NF-kB activity (p ≤ 0.03; Figure 6C, 6D), Akt 
phosphorylation (Supplementary Figure S8C) and NF-kB 
nuclear translocation (Supplementary Figure S8D).
Specific inhibitors of ERK1–2, RhoA kinase 
and HIF-1α reverse the MDR phenotype of  
IGHV UM cells
We also tested the activity of specific inhibitors 
targeting ERK1–2 kinases (PD98059, PD), RhoA kinase 
(Y27632, Y276) and HIF-1α (YC-1) in IGHV UM cells 
cultured alone or in the presence of SCs. Of note, the three 
inhibitors, as well as the upstream Mev pathway inhibitor 
SIM, had no impact on SCs viability after 48 hours of 
culture and did not increase the cytotoxic activity of Doxo 
toward SCs (Supplementary Figure S10).
In IGHV UM CLL cells, PD and Y276 markedly 
reduced HIF-1α phosphorylation (Supplementary Figure 
S11). Moreover, PD, Y276 and YC-1 reduced HIF-1α 
activity (Figure 7A) and MDR1 expression (Figure 7B), 
and increased intracellular Doxo accumulation (p always 
≤ 0.0048) (Figure 7C) and Doxo-mediated cytotoxicity 
Figure 3: SCs upregulate the Mev pathway activity, the RhoA/RhoA kinase cascade and the HIF-1α/Pgp axis in IGHV 
UM but not in IGHV M CLL cells. The production of cholesterol and FPP A. the amount of GTP­bound RhoA and the activity of the 
RhoA kinase B. the transcriptional activity of HIF-1α and the expression of the MDR1 gene C. were higher in IGHV UM cells cultured for 
24 hours with M2–10B4 SCs compared to IGHV UM cells cultured alone (*p always ≤ 0.002). SCs did not have a significant impact on the 
activity of the Mev pathway and downstream molecules in IGHV M cells. In all panels, bars represent mean values ± SEM of side-by-side 
experiments performed in replicates.
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(p ≤ 0.0001) (Figure 7D and Supplementary Figure S12–
S13) in IGHV UM cells, both in the absence and in the 
presence of SCs.
These results provided the proof­in­principle that 
inhibition of the Ras/ERK1–2/HIF-1α and RhoA/RhoA 
kinase/HIF-1α cascades, and the down-regulation of 
MDR1 gene expression and Pgp activity are mechanisms 
exploited by SIM to restore the chemosensitivity of 
MDR+ IGHV UM cells.
DISCUSSION
This study shows that IGHV UM cells are endowed 
with a MDR phenotype which grants them a greater 
resistance to Doxo­induced cytotoxicity compared with 
IGHV M cells. Mechanistic insights have shown that 
IGHV UM cells, according to their accelerated Mev 
pathway activity [15], had significantly higher activity of 
the Mev-regulated Ras/ERK1–2 and RhoA/RhoA kinase 
signaling cascades, increased HIF-1α phosphorylation 
and activity, higher MDR1 gene expression, very effective 
Doxo extrusion and enhanced survival compared with 
IGHV M cells. The MDR signature of IGHV UM cells is 
at least partially dependent on BCR signaling, as shown 
by the inhibitory effect exerted by ibrutinib on the Mev 
pathway and Mev­regulated signaling.
The constitutive MDR features of IGHV UM cells 
are further exacerbated by the incubation with SCs, which 
stimulates the Mev pathway and its downstream signaling 
cascades. Mev pathway manipulation with SIM, and 
specific ERK1–2, RhoA kinase or HIF-1α inhibitors reset 
the chemosensitivity of IGHV UM cells to the same levels 
of IGHV M cells, and neutralize the MDR­enhancing 
effect operated by SCs.
A role for MDR1 in CLL chemoresistance has 
previously been suggested by the association of Pgp 
expression with IGHV UM genes and poor prognosis 
cytogenetics [23]. Our data confirm that the MDR1 
gene, which is a primary transcriptional target of HIF-1α 
[24, 25], is constitutively more expressed in IGHV UM 
than in M cells. HIF­1 is a heterodimeric transcription 
factor composed of an oxygen-induced HIF-1α and a 
Figure 4: SIM-mediated inhibition of Ras/ERK1–2 and RhoA/RhoA kinase signaling pathways. IGHV UM cells, cultured 
alone or in the presence of the murine stromal cell line M2–10B4, were exposed to 1 μM SIM. A. Cholesterol and FPP production. The 
amount of cholesterol and FPP produced by IGHV UM cells was significantly increased after 24-hour co-culture with SCs (p = 0.007 and 
p = 0.009, respectively). SIM significantly reduced the levels of cholesterol and FPP in IGHV UM cells both in the absence (p = 0.04 and 
p = 0.05, respectively) and in the presence (p = 0.03 and p = 0.01, respectively) of M2–10B4 SCs. B. Ras and ERK1–2 kinase activity. 
Co-culture with M2–10B4 SCs increased the levels of Ras-GTP and phospho-ERK1–2 kinase. SIM reduced the expression of the active 
forms of Ras and phospho-ERK1–2 kinase in IGHV UM cells, both in the absence and in the presence of SCs. Results are from two 
representative experiments (UPN, unique patient number). C. RhoA and RhoA kinase activity. Twenty four-hour co-culture with M2–10B4 
SCs significantly increased the levels of expression of RhoA GTP and RhoA Kinase (p = 0.0005 and p = 0.0024, respectively). The 
expression of RhoA-GTP and RhoA kinase was significantly reduced by SIM, both in the absence (p < 0.0001 and p < 0.0001, respectively) 
and in the presence (p < 0.0001 and p < 0.0001, respectively) of SCs. In panels A and C results are from 8 side­by­side experiments. Box 
and whiskers plots represent median values, first and third quartiles, and minimum and maximum values for each dataset.
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constitutively expressed HIF-1β subunit. During hypoxia, 
HIF-1α is positively regulated by the activation of the 
RhoA­dependent signaling cascade [16]. Under non­
hypoxic conditions, the expression and transcriptional 
activity of HIF-1α are regulated by growth factors and 
cytokines through the activation of kinase pathways, 
such as the Ras/ERK1–2 and the PI3k/Akt pathways 
[17]. Unlike their normal counterparts, CLL cells express 
HIF-1α even under normoxia [26], and its transcriptional 
activity regulates CLL cells survival by inducing the 
expression of growth factors, such as VEGF, and the 
cytokines macrophage migration­inhibition factor (MIF) 
and midkine [26–28]. This is the first report showing 
that HIF-1α activity is significantly higher in IGHV UM 
than in M cells, due to the higher activity of the upstream 
Ras/ERK1–2 and RhoA/RhoA kinase signaling cascades 
in these cells. The MDR signature of IGHV UM cells is 
partially dependent on their tonic BCR signaling, as shown 
by the inhibitory effect exerted by ibrutinib but the lack of 
stimulatory effect exerted by anti­IgM.
Differently from anti­IgM­mediated BCR stimulation, 
SCs exposure further increase the activity of Ras/ERK1–2 
and RhoA/RhoA kinase signaling pathways and HIF-1α 
in IGHV UM cells. As a result, the target gene MDR1 is 
over-expressed, Doxo is more efficiently extruded and 
IGHV UM cells are further protected from Doxo­induced 
cytotoxicity. SCs are known to confer chemoresistance to 
CLL cells. One of the main players of the SC­induced MDR 
is the CXCL12/CXCR4 axis, which is known to activate 
the signal transducers ERK1–2 and Akt, and trigger LFA1 
affinity to the integrin ICAM-1, through a RhoA-mediated 
mechanism [29]. It is already known that the BCR signaling 
modulates the activity of the CXCL12/CXCR4 axis, in fact 
the blockade of the BCR signaling with a BTK inhibitor 
decreases the migration of CXCR4­expressing CLL cells 
toward CXCL12 produced by SCs [30].
Figure 5: SIM-mediated inhibition of HIF-1α activity and MDR1 gene expression improves Doxo-induced 
cytotoxicity. IGHV UM cells, cultured alone or in the presence of the murine stromal cell line M2–10B4, were exposed to 1 μM SIM. 
A. HIF-1α activity. The activity of HIF-1α was significantly increased by 24-hour co-culture with M2–10B4 SCs (p = 0.0007). SIM 
significantly reduced HIF-1α activity in IGHV UM cells, both in the absence (p = 0.003) and in the presence (p < 0.0001) of M2–10B4 
SCs. B. MDR1 expression. Co-culture with M2–10B4 SCs significantly increased the levels of expression of MDR1 in IGHV UM cells (p 
< 0.0001). After 24-hour exposure to SIM, a significant decrease in MDR1 expression was observed in IGHV UM cells, both in the absence 
(p < 0.0001) and in the presence (p < 0.0001) of SCs. C. Doxo intracellular accumulation. The amount of intracellular Doxo in IGHV UM 
cells was significantly reduced by co-culture with M2–10B4 SCs (p = 0.010). SIM significantly increased 48-hour Doxo accumulation in 
IGHV UM cells cultured alone (p = 0.0026) or in the presence of SCs (p = 0.0002). D. Percentage of CD19+/CD5+ viable cells. IGHV 
UM cells were exposed to 1 μM Doxo, 1 μM SIM, and the combination SIM+Doxo for 48 hours, both in the absence and in the presence 
of M2–10B4 SCs. Cell viability was determined by Ann-V staining and cytofluorimetric analysis on CD19+/CD5+ cells. No decrease in 
viability was observed when IGHV UM cells were exposed to SIM and Doxo used alone (91% ± 2% and 90% ± 1% of CD19+/CD5+ 
viable cells, respectively). By contrast, a significant reduction in cell viability was induced by the combination SIM+Doxo, both in the 
absence (19, 5% ± 7% CD19+/CD5+ viable cells, p < 0.0001) and in the presence (10% ± 3% CD19+/CD5+ viable cells, p < 0.0001) of 
SCs. In panels A-D results are from 8 side-by-side experiments. Box and whiskers plot represent median values, first and third quartiles, 
and minimum and maximum values for each dataset.
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The Mev pathway and the CXCL12/CXCR4 axis 
may reciprocally affect their activity, as shown by at least 
two observations: 1) for optimal signaling CXCR4 must be 
incorporated into membrane lipid rafts, whose formation 
require membrane cholesterol, and which orchestrate the 
interaction of the small GTPases Rac and Rho with their 
downstream transducers [31]; 2) hypercholesterolemia 
induces the secretion of CXCL12 and drives the migration 
of CD19+/CXCR4+ B lymphocytes from the bone marrow 
to the peripheral blood by interfering with the CXCL12/
CXCR4 axis [32]. Further studies aiming at elucidating the 
connections between the Mev pathway and the CXCL12/
CXCR4 axis in CLL are currently ongoing in our laboratory.
Statins and aminobisphosphonates, by targeting 
key enzymes in the Mev pathway, cause the intracellular 
deprivation of isoprenoid moieties such as FPP and 
GGPP, thus preventing Ras and RhoA prenylation and the 
activation of their downstream signaling pathways [33]. 
We have recently reported that ZA effectively interrupts 
Ras­ and RhoA­dependent downstream signalling 
pathways, abrogates Pgp expression, and restores Doxo­
induced cytotoxicity in MDR+ human cancer cell lines 
derived from solid tumors [14]. In CLL, ZA was not an 
ideal chemosensitizing agent since it inhibited Ras/ERK1–
2 and RhoA/RhoA kinase signaling pathways, HIF-1α 
activity, and MDR1 expression, but did not increase Doxo­
induced cytotoxicity. By contrast, SIM was effective in 
reversing the resistance of IGHV UM cells to Doxo, also 
in the presence of the protective effect exerted by SCs. 
This different efficacy was due to a stronger ability of SIM 
to increase the intracellular amount of Doxo, especially in 
the presence of SCs, but also to a differential regulatory 
effect exerted by the two compounds on the pro­survival 
factors Akt and NF-kB. We have already reported 
that ZA induces the activation of NF-kB in tumor-
associated macrophages, reverting their phenotype from 
tumor­permissive into tumoricidal cells [34]. A similar 
upregulation of the Akt/NF-kB pathway was observed in 
IGHV UM cells after ZA, but not after SIM exposure. This 
at least partially accounted for a ZA­mediated pro­survival 
activity which most likely prevailed on the death signals 
triggered by Doxo.
Among the chemo­sensitizing agents that we have 
tested, statins are the best candidate for clinical translation, 
since they are commonly used in the clinical practice as 
cholesterol­lowering agents. Previous data have shown that 
SIM, although potently effective in blocking the proliferation 
and inducing apoptosis of CLL cells in vitro [35–37], is not 
capable of significantly reducing the tumor burden when 
administered as a single agent in previously untreated 
Figure 6: SIM effectively counteracts SC-induced Akt upregulation in IGHV UM cells. IGHV UM cells had constitutive 
higher levels of Akt activity (p < 0.001) compared to IGHV M cells A. By contrast, there was no difference in baseline NF-kB activity 
between IGHV M and UM cells B. The Akt activity was further upregulated by the co-culture of IGHV UM cells with M2–10B4 SCs  
(p < 0.0001). SIM reduced baseline levels of Akt activity (p = 0.0082), and significantly counteracted SC-induced Akt upregulation  
(p = 0.0004) C. NF-kB activity was not upregulated by SCs, but it was significantly reduced by SIM exposure, both in the absence (p = 0.02) 
or presence of SCs (p = 0.034) D. In panels A and B bars represent mean values ± SEM. In panels C and D results are from 8 side-by-side 
experiments, and box and whiskers plot represent median values, first and third quartiles, and minimum and maximum values for each 
dataset.
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CLL patients [37]. By contrast, statins effectively increase 
the susceptibility of both drug­sensitive and drug­resistant 
CLL and lymphoma cells to dexamethasone and cytotoxic 
drugs [38], even synergizing with purine analogs to induce 
apoptosis of CLL cells [35]. Schmidmaier et al. have already 
reported that the Mev pathway and the downstream RhoA/
RhoA kinase signaling pathway mediate SC­induced MDR, 
and that targeting of this pathway by SIM may improve 
the efficacy of anti-myeloma therapies by reduction of SC-
induced MDR [39]. The same authors showed in a phase II 
clinical trial that SIM could overcome MDR in refractory 
myeloma receiving chemotherapy with bortezomib or 
bendamustine [40]. In the CLL setting, Chae et al. recently 
reported data on a retrospective analysis showing that 
the use of statin and aspirin is associated with improved 
outcome in CLL patients receiving salvage fludarabine, 
cyclophosphamide and rituximab (FCR) chemotherapy 
[41], providing the rationale for a prospective study aimed 
at evaluating the effects of statins in CLL patients receiving 
chemoimmunotherapy. Since none of the drugs included in 
the FCR regimen are substrates of the Pgp, further studies 
aimed at determining the role and mechanism of action of 
statins in chemo­sensitizing CLL cells are warranted.
Doxo accumulation as a read­out assay to test Pgp 
activity could be considered a limitation of our study, due 
to previous data showing that the addition of anthracyclines 
to alkylating agents did not improve the clinical outcome of 
CLL patients [8]. More recently, however, the addition of 
mitoxantrone or epirubicine to fludarabine-based regimens 
has been shown to improve response rates [42–44]. Skribek 
et al. have reported that anthracyclines can have direct 
cytotoxic effects on CLL cells in vitro irrespectively to 
age, clinical stage or cytogenetic markers like del(17p) 
[45]. These observations and our data are strong incentives 
Figure 7: Specific inhibitors of RhoA, ERK1–2 and HIF-1α effectively reverse the MDR phenotype of IGHV UM 
cells. IGHV UM cells were left untreated or treated with the ERK1–2 kinase inhibitor PD (10 μM), the RhoA kinase inhibitor Y276 (10 
μM) and the HIF-1α inhibitor YC-1 (10 μM), both in the absence and in the presence of M2–10B4 SCs. A. HIF-1α activity. Co-culture with 
M2–10B4 SCs significantly increased the activity of HIF-1α (p = 0.0014). PD, Y276 and YC-1 significantly reduced the activity of HIF-
1α in IGHV UM cells after 24 hours of culture, both in the absence (p always ≤ 0.0048) and in the presence (p always ≤ 0.0052) of SCs.  
B. MDR1 expression. Twenty four-hour co-culture with M2–10B4 SCs significantly increased the expression of MDR1 in IGHV UM cells  
(p < 0, 0001). After PD, Y276 and YC-1 treatment a significant decrease in MDR1 expression was observed in IGHV UM cells cultured 
alone (p always ≤ 0.001) and in the presence of SCs (p always ≤ 0.0001). C. Doxo intracellular accumulation. Intracellular Doxo was 
significantly lower in IGHV UM cells cultured with SCs than in IGHV UM cells cultured alone (p = 0.02). After 48­hour exposure to PD, 
Y276 and YC-1, Doxo accumulation was significantly increased, both in the absence (p always ≤ 0.003) and in the presence of M2–10B4 
SCs (p always ≤ 0.0012). D. Percentage of CD19+/CD5+ viable cells. IGHV UM cells were exposed to 1 μM Doxo, used alone and in 
combination with each inhibitor (i.e. PD+Doxo, Y276+Doxo, YC-1+Doxo), both in the absence and in the presence of the M2–10B4 SCs. 
Cell viability was determined by Ann-V staining and cytofluorimetric analysis on CD19+/CD5+ cells after 48-hours of culture. Doxo alone, 
as well as the three inhibitors used as single agents, did not induce a decrease in cell viability. By contrast, the combinations PD+Doxo, 
Y276+Doxo and YC-1+Doxo significantly reduced the viability of IGHV UM cells both in the absence and in the presence (p always < 
0.0001) of SCs. In panels A–D results are from 7 side-by-side experiments. Box and whiskers plot represent median values, first and third 
quartiles, and minimum and maximum values for each dataset.
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to reconsider the therapeutic potential of anthracyclines in 
CLL, especially when used in combination with chemo­
sensitizing agents targeting the Mev pathway such as 
statins, to treat specific subsets of high-risk CLL patients 
(e.g. IGHV UM patients). Moreover, the chemo­sensitizing 
effects that we observed by targeting ERK1–2 and RhoA 
kinase, as well as the transcription factor HIF-1α, in 
addition to providing a confirmatory evidence about the 
mechanistic role played by these pathways in the MDR+ 
phenotype of IGHV UM cells, opens new perspectives on 
innovative targets amenable to therapeutic interventions.
Interestingly, recent data have shown that Pgp may 
be involved in the decreased anti-cancer efficiency and 
modified pharmacological properties of novel targeted 
agents, such as imatinib [46] and second­generation 
tyrosine kinase inhibitors [47]. Therefore, the study of Pgp 
activity and its modulation might have a broad impact in 
the current era of targeted therapies, providing important 
information on the pharmacokinetic and the anti­cancer 
effects of these novel agents.
MATERIALS AND METHODS
Patients
Peripheral blood (PB) samples were collected 
from 63 untreated CLL patients between March 2008 
and November 2012 after informed consent. Patient 
demographics and clinical characteristics are reported in 
Supplementary Table S1. CLL was defined by clinical 
examination, PB cell count and immunophenotypic 
criteria. Tumor IGHV rearrangements were amplified 
starting from genomic DNA and sequences with deviations 
of < 2% or ≥ 2% from the germline IGHV sequence were 
considered IGHV UM or M as previously reported [48].
Cell purification and cell lines
Peripheral blood mononuclear cells (PBMC) from 
IGHV M and UM patients were isolated from fresh samples 
by density gradient centrifugation (Ficoll-Histopaque, PAA 
Laboratories GmbH, Linz, Austria). PBMC were used 
without further manipulation when they contained more 
than 90% of CLL cells (CD19+/CD5+). When CLL cells 
were ≤ 90% they were purified by negative selection using 
a Magnetic Bead­Activated Cell Sorting (MACS®) with a 
B Cell Isolation Kit II (Miltenyi Biotec, Bologna, Italy).
In selected experiments, the murine marrow­derived 
stromal cell line M2–10B4 (ATCC # CRL-1972) was used.
Chemicals
Electrophoresis reagents were obtained from Bio-
Rad Laboratories (Hercules, CA, USA). The protein 
content of cell lysates was assessed with the bicinchoninic 
acid kit from Sigma Chemical Co (St. Louis, MO, USA). 
ZA was a kind gift from Novartis (Basel, Switzerland). 
SIM and Y276 were purchased from Calbiochem (San 
Diego, CA, USA). When not otherwise specified, all the 
other reagents were purchased from Sigma Chemical Co.
Culture and co-culture conditions
CLL cells were cultured in 24­well plates (Costar, 
Cambridge, MA, USA) (106 cells/well) at 37°C in a 5% 
CO2 humidified incubator. The standard culture medium 
was RPMI 1640 (Euroclone, Milano, Italy) supplemented 
with 10% FCS (Euroclone), 2 mM L-glutamine, 100 U/ml 
penicillin and 100 μg/ml streptomycin.
For co-culture experiments, the M2–10B4 murine 
SCs were harvested through Trypsin-EDTA (Sigma-Aldrich, 
Milano, Italy) digestion and plated (150 × 103 cells/well) 
in complete culture medium for 24 hours. CLL cells (1 × 
106 cells/well) were added to the culture the following day. 
In selected experiments, IGHV M and UM CLL cells were 
exposed to ZA 1 μM, SIM 1 μM, ERK1–2 kinase inhibitor 
PD 10 μM, HIF-1α inhibitor YC-1 10 μM, RhoA kinase 
inhibitor Y276 10 μM, in the absence and in the presence 
of Doxo 1 μM. In selected experiments, CLL cells (5 × 106 
cells/well) were pre-incubated in complete RPMI medium 
with or without ibrutinib (1 μM) for 30 minutes at 37°C, 
and then stimulated for 24 hours with 10 μg/well anti-
IgM polyclonal goat F(ab’)2 (Southern Biotechnologies 
Birmingham, AL, USA) immobilized on 24­wells plates.
Mev pathway activity
After 24 hours of culture, 1 × 106 CLL cells were 
incubated for another 24 hours with 1 μCi of [3H]acetate 
(3600 mCi/mmol; Amersham International, Piscataway, 
NJ, USA) to measure the intracellular synthesis of 
cholesterol and FPP. Lipids were extracted in methanol/
hexane, resolved by thin layer chromatography and 
quantified by liquid scintillation counting as reported 
in [15]. According to the titration curve, the results are 
expressed as fmol/1 × 106 cells.
Ras and RhoA activity
To evaluate Ras and RhoA activity, their GTP­bound 
fraction, taken as an index of the G­protein activation [49], 
was measured after 24 hours of culture. Ras­GTP was detected 
in a pull­down assay as previously reported [50]; RhoA­GTP 
binding was measured with the G­LISA RhoA Activation 
Assay Biochem Kit (Cytoskeleton Inc, Denver, CO, USA), 
according to the manufacturer’s instructions. For each set 
of experiments a titration curve was prepared using serial 
dilution of the RhoA­GTP positive control of the kit. Data are 
expressed as U absorbance/mg cell proteins (U mg/prot).
RhoA kinase activity
RhoA kinase activity was measured after 24 hours of 
culture on 2 × 106 cells with the CycLex Rho Kinase Assay 
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Kit (CycLex Co., Nagano, Japan), as already described 
[50]. For each set of experiments a titration curve was set 
using serial dilution of recombinant RhoA kinase (Rock2, 
MBL Inc., Woburn, MA, USA). Data are expressed as U 
absorbance/mg cell proteins (U mg/prot).
Western blot (WB)
After 24 hours of culture 2 × 106 cells were lysed 
in MLB buffer (125 mM Tris-HCl, 750 mM NaCl, 1% 
v/v NP40, 10% v/v glycerol, 50 mM MgCl2, 5 mM 
EDTA, 25 mM NaF, 1 mM NaVO4, 10 μg/ml leupeptin, 
10 μg/ml pepstatin, 10 μg/ml aprotinin, 1 mmol/L 
phenylmethylsulfonyl fluoride, pH 7.5), sonicated 
(with two bursts of 10 s; Labsonic sonicator, Sartorius 
Stedim Biotech S.A., Aubagne Cedex, France), and 
centrifuged at 13000 × g for 10 min at 4°C. Ten μg cell 
lysates were subjected to SDS-PAGE, transferred to 
polyvinylidene fluoride membrane sheets (Immobilon-P, 
Millipore, Billerica, MA, USA) and probed with the 
following antibodies: anti phospho-(Thr202/Tyr204, 
Thr185/Tyr187)-ERK1–2 (Millipore); anti-ERK1–2 
(Millipore); anti­phospho­(Ser473)­Akt (Millipore); 
anti­Akt (Millipore); anti­ glyceraldehyde­3­phosphate 
dehydrogenase (GAPDH, used as control of equal protein 
loading; Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA), followed by the secondary peroxidase­conjugated 
antibodies (Bio­Rad). Proteins were detected by enhanced 
chemiluminescence (PerkinElmer, Waltham, MA, USA).
HIF-1α activity
Nuclear proteins from 2 × 106 cells were extracted 
after 24-hour culture using the Nuclear Extract Kit (Active 
Motif, Rixensart, Belgium), and quantified. The activity 
of HIF-1α was assessed on 10 μg nuclear extracts using 
the TransAM™ HIF-1α Transcription Factor Assay Kit 
(Active Motif), according to manufacturer’s instructions. 
To assess the procedure specificity, a competition assay 
was performed by adding an excess (20 pmol) of HIF-1α 
consensus oligonucleotide to nuclear extracts derived from 
CLL cells. Data are expressed as U absorbance/mg cell 
proteins (U mg/prot).
Real-time polymerase chain reaction (RT-PCR)
After 24 hours of ex vivo culture, total RNA was 
extracted from 1 × 106 cells and reverse­transcribed 
using the QuantiTect Reverse Transcription Kit 
(Qiagen, Hilden, Germany). RT­PCR was carried 
out using IQ− SYBR Green Supermix (Bio­Rad), 
according to the manufacturer’s instructions. The 
sequences of MDR1 primers were 5′-TGCTGGAGCGG 
TTCTACG-3′, 5′-ATAGGCAATGTTCTCAGCAATG-3′. 
The sequences of GAPDH primers were 5′-GA 
AGGTGAAGGTCGGAGT-3′, 5′-CATGGTGGAAT 
CATATTGGAA-3′. The relative expression of each sample 
was performed comparing the MDR1 PCR product with the 
GAPDH product, used as a housekeeping gene, with the 
Bio-Rad Software Gene Expression Quantitation (Bio-Rad).
NF-kB and Akt activity
NF-kB activity was measured on 10 μg nuclear 
extracts using the TransAM Flexi NF-kB Family assay 
kit (Active Motif), according to the manufacturer’s 
instructions. To assess the procedure specificity, a 
competition assay was performed by adding an excess 
(20 pmol) of the probe containing the NF-kB consensus 
sequence to the positive control nuclear extracts provided 
by the kit.
Akt activity was measured on 2 × 106 cells with the 
CycLex Akt/PKB Kinase Assay/Inhibitor screening kit 
(CycLex Co.) in 96­well plates pre­coated with the Akt 
substrate AkTide­2T, according to the manufacturer’s 
instructions. The titration curve was prepared using serial 
dilutions of recombinant Akt (CycLex Co.).
NF-kB and Akt activity are expressed as U 
absorbance/mg cell proteins (U mg/prot).
Intracellular doxorubicin accumulation
To evaluate the activity of Pgp the intracellular 
accumulation of the Pgp substrate Doxo was measured. 
To this aim, 1 × 106 cells were incubated with 1 μM Doxo 
cultured alone or in presence of inhibitors for 48 hours; 
intracellular Doxo was measured spectrofluorimetrically, at 
excitation and emission wavelengths of 475 and 553 nm, as 
reported earlier [50]. A blank was prepared in the absence 
of cells in each set of experiments, and its fluorescence was 
subtracted from that measured in each sample. Fluorescence 
was converted in nmol Doxo/mg cell proteins (nmol/mg 
prot) using a previously prepared calibration curve.
Quantification of apoptotic and viable cells
After 48 hours of culture, cells were harvested, 
washed in PBS and stained with anti­CD19 PerCP 
(Beckman Coulter, Milano, Italy) and anti­CD5 APC 
(Dako SpA, Milano, Italy) monoclonal antibodies. 
The percentage of apoptotic cells was determined by 
Annexin-V (Ann-V) staining with the MEBCYTO-
Apoptosis Kit (MBL Medical and Biological Laboratories, 
Naka-ku Nagoya, Japan). Flow cytometry was performed 
with a FACSCalibur and CELLQuest software (Becton 
Dickinson, Mountain View, CA, USA).
Statistical analysis
Statistical analysis was performed with the SigmaStat 
3.5 software (Systat Software Inc., Chicago, IL, USA) and 
with GraphPad Prism version 5.01 for Windows (GraphPad 
Software, San Diego, CA, USA). All datasets were evaluated 
with a normality test: data with Gaussian or approximately 
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Gaussian distribution were compared by t­test, in all other 
cases a Mann­Whitney rank sum test was used. When 
experiments involved different culture conditions of the same 
sample a repeated­measures analysis was done.
Results are expressed as mean ± SEM, unless 
otherwise specified.
Statistical significance was defined as p value < 0.05.
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MATERIALS AND METHODS
HIF-1α phosphorylation
To assess HIF-1α phosphorylation the whole cell 
lysate was immunoprecipitated with a polyclonal anti-
HIF-1α antibody (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA), then probed with a biotin-conjugated 
anti-phosphoserine antibody (Sigma Chemical Co., 
St. Louis, MO, USA) and subjected to a streptavidin-
horseradish peroxidase-conjugated polymer (Sigma 
Chemical Co.).
NF-kB nuclear translocation
Nuclear proteins from 2 × 106 cells were extracted 
after 24-hour culture using the Nuclear Extract Kit 
(Active Motif, Rixensart, Belgium), and quantified. 
Ten μg nuclear extracts were probed with the following 
antibodies: anti-p50 (Santa Cruz Biotechnology Inc.), 
anti-p65 (Santa Cruz Biotechnology Inc.), anti-TATA box 
binding protein (TBP, used as control of equal protein 
loading; Santa Cruz Biotechnology Inc.), followed by the 
secondary peroxidase-conjugated antibodies (Bio-Rad, 
Hercules, CA, USA). Proteins were detected by enhanced 
chemiluminescence (PerkinElmer, Waltham, MA, USA).
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Supplementary Figure S1: Phosphorylation of HIF-1α in IGHV M and UM CLL cells. HIF-1α phosphorylated on 
serine (pHIF-1α) and total HIF-1α expression in IGHV M and UM cells were measured by Western blot analysis. IGHV UM cells 
had a higher baseline expression of pHIF-1α than M cells (UPN, unique patient number). Results are from three representative 
experiments performed in each group of patients.
SUPPLEMENTARY FIGURES AND TABLE
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Supplementary Figure S2: Viability of IGHV M and UM CLL cells treated with Doxo. Representative analyses of Ann-V 
expression gating on CD19+/CD5+ IGHV M and UM cells (UPN, unique patient number) after 48-hour exposure to RPMI A, B. or Doxo 
C, D. Doxo induced a significant decrease in the viability of IGHV M but not UM cells.
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Supplementary Figure S3: SIM-mediated increase of HIF-1α phosphorylation in IGHV UM cells. IGHV UM cells, 
cultured alone or in the presence of the murine stromal cell line M2–10B4, were exposed to 1 μM SIM. Co-culture with M2–10B4 SCs 
increased the phosphorylation of HIF-1α. The activity of HIF-1α was reduced by SIM, both in the absence and presence of M2–10B4 
SCs. Assessment of HIF-1α phosphorylation was performed as reported in Materials and Methods. Results are from one representative 
experiment.
Supplementary Figure S4: Viability of IGHV UM CLL cells treated with Doxo, SIM and Doxo+SIM. Representative 
analyses (UPN, unique patient number) of Ann-V expression gating on CD19+/CD5+ IGHV UM cells exposed for 48 hours to RPMI, 
Doxo, SIM, and the combination SIM+Doxo, in the absence A–D. and in the presence E–H. of the murine stromal cell line M2–10B4. 
Viability of IGHV UM cells was unaffected by SIM and Doxo used as single agents, whereas it was markedly decreased by the SIM+Doxo 
combination (D), also when CLL cells were co-cultured with the M2–10B4 SCs (H).
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Supplementary Figure S5: ZA-mediated inhibition of Ras/ERK1–2 and RhoA/RhoA kinase signaling pathways. IGHV 
UM cells, cultured alone or in the presence of the murine stromal cell line M2–10B4, were exposed to 1 μM ZA. A. Cholesterol production. 
Co-culture with M2–10B4 SCs increased the levels of cholesterol in IGHV UM cells after 24 hours. Cholesterol production was inhibited 
by ZA in the absence (p = 0.05) and in the presence of SCs (p = 0.009). B. FPP production. Co-culture with M2–10B4 SCs increased the 
levels of FPP in IGHV UM cells (p = 0.006) after 24 hours of culture. FPP production was significantly inhibited by ZA in the absence 
(p = 0.05) and in the presence of SCs (p = 0.03). C, D. Ras and ERK1–2 kinase activity. Twenty four-hour co-culture with M2–10B4 
SCs increased the expression of the active forms of Ras (Ras-GTP) and ERK1–2 kinase (pERK1–2) in IGHV UM cells. ZA reduced the 
expression of Ras-GTP (C) and pERK1–2 (D) in IGHV UM cells, both in the absence and in the presence of SCs. The results are from two 
representative experiments (UPN, unique patient number). E, F. RhoA-GTP and Rho Kinase activity. Twenty four-hour co-culture with 
M2–10B4 SCs significantly increased the levels of expression of RhoA-GTP and RhoA Kinase (p = 0.01 and p = 0.003, respectively). ZA 
reduced the expression of RhoA-GTP and RhoA Kinase in IGHV UM cells both in the absence (p = 0.03 and p = 0.004, respectively) and 
in the presence (p = 0.003 and p = 0.001, respectively) of SCs. Box and whiskers plot represent median values, first and third quartiles, and 
minimum and maximum values for each dataset (A, B and E, F).
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Supplementary Figure S6: ZA-mediated increase of HIF-1α phosphorylation in IGHV UM cells. IGHV UM cells, cultured 
alone or in the presence of the murine stromal cell line M2–10B4, were exposed to 1 μM ZA. Co-culture with M2–10B4 SCs increased 
the phosphorylation of HIF-1α (pHIF-1α). The expression of pHIF-1α was reduced by ZA, both in the absence and presence of M2–10B4 
SCs. Assessment of HIF-1α phosphorylation was performed as reported in Materials and Methods. Results are from one representative 
experiment.
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Supplementary Figure S7: ZA is effective in inhibiting HIF-1α activity and MDR1 gene expression, but not in 
sensitizing IGHV UM cells to Doxo-induced cytotoxicity. A, B. HIF-1α activity and MDR1 expression. Twenty four-hour co-
culture with M2–10B4 SCs significantly increased the activity of HIF-1α (p = 0.03) and the expression of MDR1 (p = 0.01) in IGHV UM 
cells. HIF-1α activity and MDR1 expression were significantly reduced by ZA, both in the absence (p = 0.05 and p = 0.01, respectively) 
and in the presence (p = 0.04 and p = 0.03, respectively) of the murine stromal cell line M2–10B4. C. Intracellular Doxo accumulation. Co-
culture of IGHV UM cells with M2–10B4 SCs reduced the levels of intracellular Doxo (p = 0.01). After 48 hours of culture, no increase in 
intracellular Doxo was observed in IGHV UM cells treated with ZA, both in the absence and presence of M2–10B4 SCs. D. Percentage of 
CD19+/CD5+ viable cells. IGHV UM cells were exposed to 1 μM Doxo, 1 μM ZA, and the combination ZA+Doxo for 48 hours, both in the 
absence and in the presence of SCs. Doxo and ZA+Doxo did not induce cell cytotoxicity, as shown by the high percentage of viable cells 
in all culture conditions. In all panels box and whiskers plot represent median values, first and third quartiles, and minimum and maximum 
values for each dataset.
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Supplementary Figure S8: Phosphorylation of Akt and nuclear translocation of NF-kB in CLL cells. Expression of Akt 
phosphorylated on serine 473 (pAkt) and total Akt in whole cells lysates A, C. and expression of the NF-kB components p50 and p65 in 
nuclear extracts B, D. of CLL cells, measured by Western blot analyses. (A) IGHV UM cells had higher baseline expression of pAkt than 
M cells (UPN, unique patient number). (B) By contrast, there was no difference in p50 and p65 expression between IGHV M and UM cells. 
Co-culture with M2–10B4 SCs increased the phosphorylation of Akt (C), but not the nuclear translocation of NF-kB (D). SIM markedly 
reduced Akt phosphorylation, both in the absence and presence of M2–10B4 SCs (C), whereas it only slightly reduced the nuclear levels 
of p50 and p65 (D). In panels A and B, results are from three representative experiments performed in each group of IGHV M and UM 
patients; in panels C and D results are from two representative experiments performed on IGHV UM cells.
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Supplementary Figure S9: Akt and NF-kB activity in CLL cells. A. Akt activity in IGHV UM cells was significantly upregulated 
by co-culture with M2–10B4 SCs (p = 0.04) and by exposure to ZA used alone (p ≤ 0.009) or in the presence of M2–10B4 SCs (p ≤ 0.05). 
B. NF-kB activity was unaffected by co-culture with M2–10B4 SCs, whereas it was significantly upregulated by ZA, both in the absence 
(p ≤ 0.05) and in the presence (p ≤ 0.04) of SCs. Box and whiskers plot represent median values, first and third quartiles, and minimum and 
maximum values for each dataset (A and B).
Supplementary Figure S10: SIM and specific inhibitors of RhoA kinase, ERK1–2 and HIF-1a do not affect M2–10B4 
SCs viability when used alone or in combination with Doxo. M2–10B4 SCs were exposed to 1 μM SIM, 10 μM PD, 10 μM 
Y276 and 10 μM YC-1, used alone or in combination with Doxo, and evaluated for cell viability. Cell viability was determined by Ann-V 
staining and cytofluorimetric analysis after 48 hours of culture. Doxo significantly reduce M2–10B4 SCs viability (p = 0.026), whereas 
SIM, PD, Y276 and YC-1 did not reduce the M2–10B4 SCs viability when used as single agents. The combinations SIM+Doxo, PD+Doxo, 
Y276+Doxo and YC-1+Doxo did not increase the cytotoxic effect of single-agent Doxo toward SCs. Results are from 3 side by side 
independent experiments. Box and whiskers plot represent median values, first and third quartiles, and minimum and maximum values for 
each dataset.
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Supplementary Figure S11: Specific inhibitors of RhoA and ERK1–2 reduce HIF-1α phosphorylation. Co-culture of 
IGHV UM cells with M2–10B4 SCs significantly increased the phosphorylation of HIF-1α. The ERK1–2 inhibitor PD (10 μM) and the 
RhoA kinase inhibitor Y27632 (Y276) (10 μM) reduced the phosphorylation of HIF-1α (pHIF-1α) in IGHV UM cells, both in the absence 
and in the presence of M2–10B4 SCs. As expected, YC-1 reduced HIF-1α activity without affecting its phosphorylation.
Supplementary Figure S12: Specific inhibitors of RhoA kinase, ERK1–2 and Hif-1a do not affect IGHV UM cells 
viability. Representative analyses (UPN, unique patient number) of Ann-V expression gating on CD19+/CD5+ IGHV UM cells exposed 
for 48 hours to RPMI, PD, Y276 and YC-1 in the absence A–D. and in the presence E–H. of M2–10B4 SCs. The 3 specific inhibitors did 
not exert a cytotoxic effect toward IGHV UM cells when used as single agents.
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Supplementary Figure S13: Specific inhibitors of RhoA, ERK1–2 and HIF-1α effectively restore Doxo sensitivity of 
IGHV UM cells. Representative analyses (UPN, unique patient number) of Ann-V expression gating on CD19+/CD5+ IGHV UM cells 
exposed for 48 hours to 1 μM Doxo, used alone A, B. or in combination with specific inhibitors of RhoA kinase (PD), ERK1–2 (Y276) and 
HIF-1α (YC-1), both in the absence B–D. and in the presence F–H. of M2–10B4 SCs. Doxo did not induce a decrease in cell viability. By 
contrast, the combinations PD+Doxo, Y276+Doxo and YC-1+Doxo markedly reduced the viability of IGHV UM cells, both in the absence 
(B–D) and in the presence (F–H) of SCs.
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Supplementary Table S1: Clinical and biological features of CLL patients
All patients UM patients
No. patients1 63 31 (49%)
Median age2, years (range) 65 (43–82) 64 (45–81)
Female, no. (%) 23 (37%) 9 (29%)
Binet stage, no. (%)3
A 49 (82%) 20 (69%)
B 8 (13%) 6 (21%)
C 3 (5%) 3 (10%)
Lymphocytes, #/μl4,5 15400 ± 1600 17900 ± 2800
Lymphocytes, %4,6 67.9 ± 2.0 67.0 ± 3.5
Hb, g/dl4,5 14.1 ± 0.2 13.8 ± 0.4
Plts, #/μl4,6 197000 ± 7100 194000 ±10800
LDH, U/ml4,7 359 ± 11 371 ± 13
β2M, g/dl4, 8 2.1 ± 0.2 2.5 ± 0.4
% B CLL clone4,9 78.4 ± 2.0 79.7 ± 2.9
CD38+, no. (%)2,10 18 (28%) 13 (43%)
ZAP70+, no. (%)2,11 13 (20%) 9 (30%)
K light chain, no. (%)5 36 (58%) 17 (59%)
Cytogenetics2normal caryotype, no. (%) 25 (41%) 13 (45%)
Del (11), no. (%) 6 (12%) 3 (10%)
Del (13), no. (%) 25 (41%) 7 (24%)
Del (17), no. (%) 7 (11%) 3 (10%)
1 All cases were evaluable for each of the variables, if not otherwise specified
2 data available in 61 patients, 30 patients for UM category
3 data available in 60 patients, 29 patients for UM category
4 data expressed as mean ± SEM
5 data available in 59 patients, 29 patients for UM category
6 data available in 58 patients, 28 patients for UM category
7 data available in 49 patients, 27 patients for UM category
8 data available in 31 patients, 17 patients for UM category
9 data available in 55 patients, 27 patients for UM category
10 CD38 expression was considered positive when >30%
11 ZAP70 expression was considered positive when >20%
